This approach to personalized drug therapy may be beneficial for patients with tamoxifen-resistant breast cancer, revealing ACK1 inhibitor treatments such as dasatinib therapy, which is already an FDA-approved drug as an adjuvant treatment regimen. This evidence concerns the gene TNK2 and breast cancer.